Curated News
By: NewsRamp Editorial Staff
July 31, 2026
Ocumetics Raises $2.5M in Second Tranche, Advances Vision Tech
TLDR
- Ocumetics secures $2.5M in second tranche, accelerating its first-in-human trials for a potentially disruptive intraocular lens technology.
- Ocumetics issued 6.25M units at $0.40, each with a warrant exercisable at $0.50 for three years, funding clinical trials and R&D.
- Ocumetics' lens aims to eliminate glasses and contacts, restoring natural vision for millions, a step toward better sight for all.
- Ocumetics' dynamic lens mimics natural eye focus, shifting from distance to near seamlessly, a marvel of biomedical engineering.
Impact - Why it Matters
This funding milestone is crucial for Ocumetics as it advances its first-in-human trials for a revolutionary intraocular lens. If successful, this technology could eliminate the need for corrective eyewear, significantly improving the quality of life for millions. For investors, it signals progress and potential market disruption in the ophthalmic industry. The successful capital raise also validates the company's strategic direction and may attract further investment, accelerating the path to commercialization.
Summary
Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a Canadian company developing advanced vision correction solutions, has completed the second tranche of its private placement, raising an additional $2.5 million. The company issued 6.25 million units at $0.40 per unit, each consisting of one common share and one warrant exercisable at $0.50 for three years. This brings total gross proceeds to date to $2,948,130, with the offering aiming for up to $3.2 million.
The funds will support Ocumetics' first-in-human clinical trials and ongoing R&D for its innovative dynamic intraocular lens, which is designed to replace corrective lenses by mimicking the eye's natural focusing ability. The company paid Ventum Financial Corp. cash commissions of $200,000 and issued 500,000 warrants for their assistance. The warrants include an acceleration clause if the stock trades at $0.75 or higher for 30 consecutive days. All securities are subject to a four-month hold period. The offering is expected to close in additional tranches, subject to TSX Venture Exchange approval.
Ocumetics is at the forefront of ophthalmic innovation, with its technology potentially eliminating the need for glasses or contact lenses. The successful funding underscores investor confidence in the company's mission to transform vision correction. For more details, view the original release on NEWMEDIAWIRE.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, Ocumetics Raises $2.5M in Second Tranche, Advances Vision Tech
